journal article·2024-03-20

Tailoring Zinc Ferrite Nanoparticle Surface Coating for Macrophage-Affinity Magnetic Resonance Imaging of Atherosclerosis

Lingyi Wen, Xiaomin Fu, Huan Zhang, Pengfei Ye, Hang Fu, Zhongqin Zhou, Ran Sun, Ting Xu, Chuan Fu, Chengcheng Zhu, Yingkun Guo, Haiming Fan

ACS Applied Materials & Interfaces· Volume 16· Issue 11
Publisher page

Abstract

Atherosclerosis is a chronic inflammatory disease characterized by the formation of atherosclerotic plaques, while macrophages as key players in plaque progression and destabilization are promising targets for atherosclerotic plaque imaging. Contrast-enhanced magnetic resonance imaging (CE-MRI) has emerged as a powerful noninvasive imaging technique for the evaluation of atherosclerotic plaques within arterial walls. However, the visualization of macrophages within atherosclerotic plaques presents considerable challenges due to the intricate pathophysiology of the disease and the dynamic behavior of these cells. Biocompatible ferrite nanoparticles with diverse surface ligands possess the potential to exhibit distinct relaxivity and cellular affinity, enabling improved imaging capabilities for macrophages in atherosclerosis. In this work, we report macrophage-affinity nanoparticles for magnetic resonance imaging (MRI) of atherosclerosis via tailoring nanoparticle surface coating. The ultrasmall zinc ferrite nanoparticles (Zn 0.4 Fe 2.6 O 4 ) as T 1 contrast agents were synthesized and modified with dopamine, 3,4-dihydroxyhydrocinnamic acid, and phosphorylated polyethylene glycol to adjust their surface charges to be positively, negatively, and neutrally charged, respectively. In vitro MRI evaluation shows that the T 1 relaxivity for different surface charged Zn 0.4 Fe 2.6 O 4 nanoparticles was three higher than that of the clinically used Gd-DTPA. Furthermore, in vivo atherosclerotic plaque MR imaging indicates that positively charged Zn 0.4 Fe 2.6 O 4 showed superior MRI efficacy on carotid atherosclerosis than the other two, which is ascribed to high affinity to macrophages of positively charged nanoparticles. This work provides improved diagnostic capability and a better understanding of the molecular imaging of atherosclerosis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cerebrovascular and Carotid Artery Diseases · Nanoparticle-Based Drug Delivery · Protease and Inhibitor Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 614001, China

Key Laboratory of Synthetic and Natural Functional Molecule Chemistry of the Ministry of Education, College of Chemistry and Materials Science, Northwest University, Xi’an 710127, China

School of Medicine, Northwest University, Xi’an 710069, China

Department of Radiology, Zhuhai People’s Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, China

Department of Radiology, University of Washington, Seattle, Washington 98105, United States

Funding

China Postdoctoral Science Foundation · National Natural Science Foundation of China · Chengdu Science and Technology Program · Sichuan Science and Technology Program

References (57)

Show source-provided references
1. 10.1038/s41573-021-00198-110.1038/s41573-021-00198-1 ↗
2. 10.1016/S2214-109X(20)30117-010.1016/S2214-109X(20)30117-0 ↗
3. 10.1038/nri352010.1038/nri3520 ↗
4. 10.1038/nm.325810.1038/nm.3258 ↗
5. 10.1056/NEJMra200031710.1056/NEJMra2000317 ↗
6. 10.1021/acsnano.6b0784210.1021/acsnano.6b07842 ↗
7. 10.1093/eurheartj/ehr06810.1093/eurheartj/ehr068 ↗
8. 10.1038/nrcardio.2009.24610.1038/nrcardio.2009.246 ↗
9. 10.1016/S0140-6736(00)04261-610.1016/S0140-6736(00)04261-6 ↗
10. 10.1148/radiol.223201065910.1148/radiol.2232010659 ↗
11. 10.1073/pnas.060628110410.1073/pnas.0606281104 ↗
12. 10.1007/s12274-023-6214-910.1007/s12274-023-6214-9 ↗
13. 10.1038/s41569-021-00629-x10.1038/s41569-021-00629-x ↗
14. 10.1016/j.atherosclerosis.2017.06.02010.1016/j.atherosclerosis.2017.06.020 ↗
15. 10.1016/j.jacc.2009.03.01810.1016/j.jacc.2009.03.018 ↗
16. 10.1161/01.CIR.0000068315.98705.CC10.1161/01.CIR.0000068315.98705.CC ↗
17. 10.1161/01.ATV.0000222920.59760.df10.1161/01.ATV.0000222920.59760.df ↗
18. 10.1136/jnnp.2007.11890110.1136/jnnp.2007.118901 ↗
19. 10.1016/j.biomaterials.2016.10.01110.1016/j.biomaterials.2016.10.011 ↗
20. 10.21037/qims.2017.02.0910.21037/qims.2017.02.09 ↗
21. 10.1039/C1CS15248C10.1039/C1CS15248C ↗
22. 10.1021/acs.chemrev.5b0011210.1021/acs.chemrev.5b00112 ↗
23. 10.1148/radiol.221200161210.1148/radiol.2212001612 ↗
24. 10.1161/01.CIR.102.9.95910.1161/01.CIR.102.9.959 ↗
25. 10.1073/pnas.162014511410.1073/pnas.1620145114 ↗
26. 10.1002/adma.20190653910.1002/adma.201906539 ↗
27. 10.1038/s41569-021-00629-x10.1038/s41569-021-00629-x ↗
28. 10.1002/smll.20170279310.1002/smll.201702793 ↗
29. 10.1002/smll.20090115810.1002/smll.200901158 ↗
30. 10.1016/j.nantod.2015.07.00210.1016/j.nantod.2015.07.002 ↗
31. 10.1002/adma.20200417210.1002/adma.202004172 ↗
32. 10.1016/j.biomaterials.2014.04.00910.1016/j.biomaterials.2014.04.009 ↗
33. 10.1021/acsnano.6b0768410.1021/acsnano.6b07684 ↗
34. 10.1021/acs.nanolett.0c0457410.1021/acs.nanolett.0c04574 ↗
35. 10.7150/thno.3123310.7150/thno.31233 ↗
36. 10.1039/D0NJ01272F10.1039/D0NJ01272F ↗
37. 10.1002/slct.20200456210.1002/slct.202004562 ↗
38. 10.1021/acs.chemmater.8b0476010.1021/acs.chemmater.8b04760 ↗
39. 10.1038/s41596-018-0057-y10.1038/s41596-018-0057-y ↗
40. 10.1097/01.rli.0000184756.66360.d310.1097/01.rli.0000184756.66360.d3 ↗
41. 10.1021/cr00081a00310.1021/cr00081a003 ↗
42. 10.1021/acsnano.6b0795910.1021/acsnano.6b07959 ↗
43. 10.7150/thno.2378910.7150/thno.23789 ↗
44. Talev, J.; Kanwar, J. R. In Iron Oxide Nanoparticles as Imaging and Therapeutic Agents for Atherosclerosis, Seminars in Thrombosis and Hemostasis; Thieme Medical Publishers: 2020; pp 553–562.10.1055/s-0039-3400247 ↗
45. 10.1016/j.jcmg.2010.08.01210.1016/j.jcmg.2010.08.012 ↗
46. 10.1007/s00330-008-0978-x10.1007/s00330-008-0978-x ↗
47. 10.1097/01.RVI.0000244836.16098.B110.1097/01.RVI.0000244836.16098.B1 ↗
48. 10.1016/j.jacbts.2021.06.00610.1016/j.jacbts.2021.06.006 ↗
49. 10.1021/acsnano.2c0731210.1021/acsnano.2c07312 ↗
50. 10.1021/acsnano.5b0132010.1021/acsnano.5b01320 ↗
51. 10.1039/C8NR10490E10.1039/C8NR10490E ↗
52. 10.1021/nn305719y10.1021/nn305719y ↗
53. 10.1021/jacs.5b0853310.1021/jacs.5b08533 ↗
54. 10.1021/ja506032410.1021/ja5060324 ↗
55. 10.1021/acsnano.6b0794210.1021/acsnano.6b07942 ↗
56. 10.1021/jacs.2c0728710.1021/jacs.2c07287 ↗
57. 10.1158/0008-5472.CAN-21-426010.1158/0008-5472.CAN-21-4260 ↗